Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 15;10(5):69-75.
eCollection 2021.

Evaluation of the effectiveness of methylphenidate and modafinil in the treatment of daily drowsiness in patients with refractory epilepsy and their comparison with the control group

Neda Sheikhina  1 , Mohammad-Reza Najafi  1 , Ahmad Chitsaz  1 , Keyvan Ghadimi  2
Affiliations

Evaluation of the effectiveness of methylphenidate and modafinil in the treatment of daily drowsiness in patients with refractory epilepsy and their comparison with the control group

Neda Sheikhina et al. Am J Neurodegener Dis. .

Abstract

Background: Various articles show the high prevalence of sleep disorders and especially excessive daytime sleepiness (EDS) in patients with refractory epilepsy and the importance of personal and social burden of this complication on individuals. Considering the insufficient evidence to draw efficacy and safety of modafinil and methylphenidate to treat EDS in the patient with intractable seizures, we decided to compare the effect of methylphenidate and modafinil with the control group. It is hoped that this study will pave the way for further studies.

Methods: This study is a clinical trial (IRCT20171030037093N22) (URL: https://www.irct.ir/trial/42485). The study population was patients with refractory epilepsy referred to the neurology clinic of Al-Zahra Hospital, Isfahan, Iran, from 2019 to 2020. The patients were randomly divided into three groups. The first group was treated with methylphenidate, the second group was treated with modafinil, and the third group was not received any medication such as modafinil and methylphenidate. Methylphenidate dosage was 10-20 mg/day. The patients were treated with modafinil at a dose of 200-600 mg/day. EPWORTH sleepiness scale (ESS) and Total Sleep Time (TST) were calculated before and 8 weeks after the intervention for the patients.

Results: 47 patients were included and divided into 3 groups, methylphenidate (10 males and 9 females), modafinil (7 males and 13 females), and control (4 males and 4 females). There was no significant difference among the groups based on ESS before and after intervention and TST after the intervention (P>0.05), but the mean of TST was significantly lower in the control group than in methylphenidate and modafinil groups before the intervention (P=0.003). The change of ESS and TST before compared to after intervention in the methylphenidate and modafinil group were significant (P<0.001), but the changes of ESS and TST in the control group were not significant (P>0.05). The frequency of complications (P=0.74) and outcomes (P=0.07) were similar in both groups.

Conclusion: Modafinil and methylphenidate are two effective and safe drugs to increase the quality of sleep in the patients. Additionally, ESS and TST scores are better in the patients who used modafinil and methylphenidate.

Keywords: Modafinil; excessive daytime sleepiness; methylphenidate; quality of life.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Changing ESS before and after intervention based on groups.
Figure 2
Figure 2
Changing TST before and after intervention based on groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ford ES, Cunningham TJ, Giles WH, Croft JB. Trends in insomnia and excessive daytime sleepiness among US adults from 2002 to 2012. Sleep Med. 2015;16:372–378. - PMC - PubMed
    1. Guilleminault C, Brooks SN. Excessive daytime sleepiness: a challenge for the practising neurologist. Brain. 2001;124:1482–1491. - PubMed
    1. Farrokhi M, Dabirzadeh M, Dastravan N, Etemadifar M, Ghadimi K, Saadatpour Z, Rezaei A. Mannose-binding lectin mediated complement pathway in autoimmune neurological disorders. Iran J Allergy Asthma Immunol. 2016;15:251–256. - PubMed
    1. Rafiee Zadeh A, Ghadimi K, Mohammadi B, Hatamian H, Naghibi SN, Danaeiniya A. Effects of estrogen and progesterone on different immune cells related to multiple sclerosis. CJNS. 2018;4:83–90.
    1. Najafi MR, Najafi MA, Shayan-Moghadam R, Saadatpour Z, Ghadimi K. Comparison of the efficacy of tegatard and tegretol as a monotherapy in patients with focal seizure with or without secondary generalization. Am J Clin Exp Immunol. 2020;9:58–63. - PMC - PubMed

LinkOut - more resources